Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, is pleased to announce the appointment of Dr Mike Owen to the Board as a non-executive director with immediate effect.

Mike brings over 15 years of experience in the development and commercialisation of biopharmaceuticals. He was previously Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK’s robust pre-clinical and clinical therapeutic antibody pipeline through in-house development and acquisitions. Since leaving GSK in 2010, he has taken on a number of executive and non-executive roles in the biotech sector. His most recent executive appointment was at Kymab where he served as the Chief Scientific Officer from its formation as a spin-out from the Sanger Institute using a mouse-model to develop a range of antibody-based therapeutics.

Mike is currently a director at Avacta plc, Blink Biomedical SAS, GammaDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. He is also an advisor to Abingworth LLP and the CRT Pioneer Fund. He holds a BA degree from Oxford University and a PhD from Cambridge University. He is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.

Commenting on the appointment, Dr Sam Williams, Chairman of Glythera, said:

"We are delighted to welcome Mike to the Board of Glythera at this exciting time in the Company’s development. His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product pipeline and building strategic partnerships with large pharma."

Dr Mike Owen said:

"I am pleased to be joining the Board of Glythera and look forward to working with the Board and management team as the Company moves its pipeline products towards the clinic. The enhanced safety and efficacy of Glythera’s PermaLink^®-based ADCs has the potential to significantly advance treatment and improve patient outcomes."

For enquiries, please contact:

Simon Conway / Mo Noonan / Rob Winder, FTI Consulting Tel: +44 (0) 020 3727 1000

Dr Dave Simpson, CEO Glythera Limited Tel: +44 (0) 191 6031681

Notes to Editors

Glythera Limited

Glythera is a biotechnology company focussed on the development of next generation antibody drug conjugates (ADCs) designed to combat difficult-to-treat tumours, including those that are resistant or refractory to current treatment regimens. Glythera’s pipeline of safe and effective ADCs is centred on its highly stable PermaLink^® conjugation platform in combination with a portfolio of highly potent cytotoxic payloads designed to enhance antitumor activity and improve the lives of cancer patients.

For further information visit: www.glythera.com